Next step in the development of mesoprogestins: the preclinical profile of EC313
IntroductionThe pharmacological target for progesterone, different progestins, and Selective Progesterone Receptor Modulators (SPRMs) is the nuclear progesterone receptor (PR). EC313 is a new member of a subgroup of SPRMs, mesoprogestins, which combine especially PR- agonistic and PR-antagonistic ac...
Main Authors: | K. Błaszczak-Świątkiewicz, A. Krupa, E. Mnich, W. Elger, M. Oettel, H. Nair, M. Wierzbicki, P. Sieroszewski, Z. Shaked |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-09-01
|
Series: | Frontiers in Endocrinology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2023.1201547/full |
Similar Items
-
MicroRNAs and Progesterone Receptor Signaling in Endometriosis Pathophysiology
by: Warren B. Nothnick
Published: (2022-03-01) -
The role of progesterone and estrogen receptors in treatment choice after endometriosis surgery: A cross-sectional study
by: Tahereh Poordast, et al.
Published: (2024-09-01) -
Negative effect of varicocele on sperm mitochondrial dysfunction: A cross-sectional study
by: Mahshid Elahi, et al.
Published: (2024-09-01) -
Expression of estrogen and progesterone receptors in subcutaneous endometriosis
by: Đorđević M., et al.
Published: (2010-01-01) -
Progesterone Signaling and Uterine Fibroid Pathogenesis; Molecular Mechanisms and Potential Therapeutics
by: Mohamed Ali, et al.
Published: (2023-04-01)